Conference Coverage

ASH: Carfilzomib doubles progression free survival in head-to-head trial with bortezomib

Publish date: December 5, 2015

 

FROM ASH 2015

References

koakes@frontlinemedcom.com

On Twitter @karioakes

Pages

Recommended Reading

Anti-CD38 antibodies poised to transform myeloma treatment
MDedge Internal Medicine
Lenalidomide now approved for newly diagnosed multiple myeloma
MDedge Internal Medicine
Chemotherapy and stem-cell transplantation combination appears safe
MDedge Internal Medicine
Advanced age no barrier to continuous myeloma regimen
MDedge Internal Medicine
Myeloma precursor linked to Agent Orange exposure
MDedge Internal Medicine
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Internal Medicine
Multiple myeloma advances in diagnosis, staging, therapy extend survival
MDedge Internal Medicine